11 results on '"Mir, Roser"'
Search Results
2. YM155 sensitizes ovarian cancer cells to cisplatin inducing apoptosis and tumor regression
- Author
-
Mir, Roser, Stanzani, Elisabetta, Martinez-Soler, Fina, Villanueva, Alberto, Vidal, August, Condom, Enric, Ponce, Jordi, Gil, Joan, Tortosa, Avelina, and Giménez-Bonafé, Pepita
- Published
- 2014
- Full Text
- View/download PDF
3. Correction to: Routine clinical care data for population pharmacokinetic modeling: the case for Fanhdi/Alphanate in hemophilia A patients
- Author
-
Chelle, Pierre, Yeung, Cindy H. T., Bonanad, Santiago, Morales Muñoz, Juan Cristóbal, Ozelo, Margareth C., Megías Vericat, Juan Eduardo, Iorio, Alfonso, Spears, Jeffrey, Mir, Roser, and Edginton, Andrea
- Published
- 2019
- Full Text
- View/download PDF
4. Clinical Efficacy and Safety of Fanhdi ®, a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain : A Retrospective Study
- Author
-
Jiménez-Yuste, Víctor, Alvarez-Román, María Teresa, Palomo Bravo, Ángeles, Galmes, Bernardo J., Nieto Hernández, Maria del Mar, Benítez Hidalgo, Olga, Marzo Alonso, Cristina, Pérez González, Noelia Florencia, Coll, Julia, Núñez, Ramiro, Carrasco, Marina, García-Candel, Faustino, Gonzalez-Porras, Jose Ramon, Hernández García, Carmen, Varó Castro, Maria José, Mir, Roser, Universitat Autònoma de Barcelona, UAM. Departamento de Medicina, Institut Català de la Salut, [Jiménez-Yuste V, Alvarez-Román MT] Department of Hematology and Hemotherapy, Hospital Universitario La Paz, Autónoma University, Madrid, Spain. [Palomo Bravo Á] Hematology Service, Hospital Materno-Infantil de Málaga, Málaga, Spain. [Galmes BJ] Hematology Service, Hospital Universitario Son Espases, Palma de Mallorca, Spain. [Nieto Hernández MDM] Hematology and Hemotherapy Service, Complejo Universitario de Jaén, Jaén, Spain. [Benítez Hidalgo O] Servei d’Hematologia i Hemoteràpia, Vall d’Hebron Hospital Universitari, Barcelona, Spain, and Vall d'Hebron Barcelona Hospital Campus
- Subjects
Adult ,Male ,congenital, hereditary, and neonatal diseases and abnormalities ,Adolescent ,Medicina ,Blood Loss, Surgical ,Hemorrhage ,Hemostatics ,surgery ,Young Adult ,von willebrand disease ,Amino Acids, Peptides, and Proteins::Proteins::Blood Proteins::Blood Coagulation Factors::von Willebrand Factor [CHEMICALS AND DRUGS] ,hemic and lymphatic diseases ,enfermedades hematológicas y linfáticas::enfermedades hematológicas::trastornos de la coagulación sanguínea::trastornos de la coagulación sanguínea hereditarios::enfermedades de von Willebrand [ENFERMEDADES] ,Humans ,Diseases of the circulatory (Cardiovascular) system ,Plasma-derived von willebrand factor/factor VIII concentrate ,Hemic and Lymphatic Diseases::Hematologic Diseases::Blood Coagulation Disorders::Blood Coagulation Disorders, Inherited::von Willebrand Diseases [DISEASES] ,Other subheadings::/therapeutic use [Other subheadings] ,Child ,Aged ,Retrospective Studies ,Sang - Coagulació - Factor VIII ,Factor VIII ,Otros calificadores::/uso terapéutico [Otros calificadores] ,Prophylaxis ,Bleeding ,plasma-derived von willebrand factor/factor VIII concentrate ,Hematology ,General Medicine ,Middle Aged ,bleeding ,Von willebrand factor ,von willebrand factor ,Drug Combinations ,von Willebrand Diseases ,aminoácidos, péptidos y proteínas::proteínas::proteínas sanguíneas::factores de coagulación de la sangre::factor de von Willebrand [COMPUESTOS QUÍMICOS Y DROGAS] ,Spain ,RC666-701 ,Female ,Surgery ,Von willebrand disease ,prophylaxis ,Malaltia de von Willebrandt - Tractament - Abstract
To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients. Methods: A retrospective, multicentric, observational study of VWD patients treated with Fanhdi®, a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis. Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed. Conclusions: Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patients, The author(s) disclosed receipt of the followingfinancial support forthe research, authorship, and/or publication of this article: This workwas supported by Grifols, manufacturer of the pdVWF/FVIII,Fanhdi®
- Published
- 2022
5. Mdm2 antagonists induce apoptosis and synergize with cisplatin overcoming chemoresistance in TP53 wild-type ovarian cancer cells
- Author
-
Mir, Roser, Tortosa, Avelina, Martinez-Soler, Fina, Vidal, August, Condom, Enric, Pérez-Perarnau, Alba, Ruiz-Larroya, Tatiana, Gil, Joan, and Giménez-Bonafé, Pepita
- Published
- 2013
- Full Text
- View/download PDF
6. Derivation of a Pharmacokinetic Model to Include a Plasma-Derived, von Willebrand Factor-Containing Factor VIII (Koate®-DVI) Concentrate and its Low-Dose Use.
- Author
-
Hajducek, Dagmar M., Primacakti, Fitri, Chozie, Novie, Mir, Roser, McEneny-King, Alanna, Iorio, Alfonso, and Edginton, Andrea
- Subjects
HEMOPHILIA ,BLOOD coagulation tests ,BODY weight ,PHARMACOKINETICS ,GOODNESS-of-fit tests ,ENZYME-linked immunosorbent assay ,DESCRIPTIVE statistics ,BLOOD coagulation factors ,STATISTICAL correlation ,VON Willebrand disease ,DOSE-response relationship in biochemistry - Abstract
BACKGROUND: Population pharmacokinetics (popPK) has been reliably leveraged to generate individual PK in hemophilia patients. Specific popPK models are suited to predict individual PK under a variety of scenarios that may not be captured by clinical trials, allowing for individualized prophylactic treatment. The Web-Accessible Population Pharmacokinetic Service-Hemophilia (WAPPS-Hemo) project generates individually predicted pharmacokinetic profiles relying on concentrate-specific popPK models used for Bayesian forecasting. OBJECTIVE: Specification of a popPK model for the plasma-derived factor VIII (FVIII) concentrate Koate-DVI and its suitability for pharmacokinetic estimation in low-dose scenarios. METHODS: A popPK model was developed for Koate-DVI WAPPS-Hemo PK data in combination with the existing WAPPS-Hemo Fanhdi/ Alphanate model derivation dataset using nonlinear mixed effects modelling, and was validated via cross-validation and prediction-corrected Visual Predictive Checks (pcVPC). Bootstrap and PK outcomes between the Fanhdi/Alphanate and the Fanhdi/Alphanate/Koate models were compared, and the relative error distributions from a limited sampling analysis (LSA) under the latter model for low and normal doses (10 vs 50 IU/kg) and inclusion/exclusion of pre-dose measurements. RESULTS: A Fanhdi/Alphanate/Koate model was derived (126 patients, ages 1-71 years) after deeming a Koate-brand covariate not clinically significant, resulting in similar parameter estimates than the Fanhdi/Alphanate model with satisfactory goodness of fit, cross-validation and pcVPC results. Low-dose predictions resulted in a higher accuracy and slightly lower precision of half-life (^-phase) and time to 2% trough (TAT2%) estimates than normal dose (median absolute bias for half-life: 0.12 vs 0.5%; median interquartile range, IQR: 11.79% vs 9.95%). Precision improved under pre-dose designs by 2 to 3% and remained similar between 5- and 2-sample designs (IQR reduction<1.8%). CONCLUSIONS: The Fanhdi/Alphanate/Koate model is appropriate for Bayesian forecasting in the WAPPS-Hemo platform, providing a comparable prediction capability for low and normal dosing regimens (10 vs 50 IU/Kg). [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
7. Antihormonal agents as a strategy to improve the effect of chemo-radiation in cervical cancer: in vitro and in vivo study.
- Author
-
Segovia-Mendoza, Mariana, Jurado, Rafael, Mir, Roser, Medina, Luis A., Prado-Garcia, Heriberto, and Garcia-Lopez, Patricia
- Subjects
CANCER chemotherapy ,CANCER radiotherapy ,CERVICAL cancer treatment ,DRUG efficacy ,HORMONE antagonists ,CISPLATIN ,IN vitro studies - Abstract
Background Over the past few years, the concurrent use of cisplatin-based chemotherapy and radiation therapy has dramatically improved the local response and increased overall survival in early-stage cervical cancer. However, for the advanced stages of the disease this standard treatment has proved insufficient. We investigated the capacity of Mifepristone and ICI 182,780, which are anti-progestin and anti-estrogen drugs, respectively, to act as chemo-radiosensitizing agents in cervical cancer cells and cervix xenografts. Methods The effect of chemo-radiation alone or combined with Mifepristone or ICI 182,780 was evaluated in HeLa cells and with tumor growth in cervix xenografts. After concomitant chemo-radiotherapy, the effect of each of these antihormonal agents on apoptosis (determined by Annexing V assay) and the cell cycle phases were determined by flow cytometry. The expression of angiogenic factor VEGF in tumor samples was determined using quantitative RT-PCR analysis of VEGF gene expression. Results Compared to radiation alone or radiation/cisplatin therapy, there was significantly higher cytotoxicity and a greater antitumoral effect with the combined application of radiation/cisplatin and Mifepristone or ICI 182,780. Analyses of the apoptosis and cell cycle demonstrated changes only with ICI, not with Mifepristone, when was applied in combination with radiation/cisplatin. The analysis of VEGF mRNA expression levels in tumors at the end of the study demonstrated a significant inhibition, compared to radiation only or the radiation/cisplatin treatment, after concurrent chemo-radiotherapy and each one of the antihormonal drugs. Conclusion Mifepristone and ICI 182,780 may be potentially promising chemo-radiosensitizing compounds to be used in combination with ionizing irradiation and cisplatin in the treatment of patients with advanced cervical cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
8. Multidrug resistance protein 1 localization in lipid raft domains and prostasomes in prostate cancer cell lines.
- Author
-
Gomà, Alba, Mir, Roser, Martínez-Soler, Fina, Tortosa, Avelina, Vidal, August, Condom, Enric, Pérez–Tomás, Ricardo, and Giménez-Bonafé, Pepita
- Subjects
- *
MULTIDRUG resistance-associated proteins , *PROSTATE cancer treatment , *ATP-binding cassette transporters , *LIPID rafts , *EXOSOMES , *CELL lines , *CAVEOLAE , *ELECTRON microscopy - Abstract
Background: One of the problems in prostate cancer (CaP) treatment is the appearance of the multidrug resistance phenotype, in which ATP-binding cassette transporters such as multidrug resistance protein 1 (MRP1) play a role. Different localizations of the transporter have been reported, some of them related to the chemoresistant phenotype. Aim: This study aimed to compare the localization of MRP1 in three prostate cell lines (normal, androgen-sensitive, and androgen-independent) in order to understand its possible role in CaP chemoresistance. Methods: MRP1 and caveolae protein markers were detected using confocal microscopy, performing colocalization techniques. Lipid raft isolation made it possible to detect these proteins by Western blot analysis. Caveolae and prostasomes were identified by electron microscopy. Results: We show that MRP1 is found in lipid raft fractions of tumor cells and that the number of caveolae increases with malignancy acquisition. MRP1 is found not only in the plasma membrane associated with lipid rafts but also in cytoplasmic accumulations colocalizing with the prostasome markers Caveolin-1 and CD59, suggesting that in CaP cells, MRP1 is localized in prostasomes. Conclusion: We hypothesize that the presence of MRP1 in prostasomes could serve as a reservoir of MRP1; thus, taking advantage of the release of their content, MRP1 could be translocated to the plasma membrane contributing to the chemoresistant phenotype. The presence of MRP1 in prostasomes could serve as a predictor of malignancy in CaP. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
9. Liposomes Co-Encapsulating Cisplatin/Mifepristone Improve the Effect on Cervical Cancer: In Vitro and In Vivo Assessment.
- Author
-
Ledezma-Gallegos, Fabricio, Jurado, Rafael, Mir, Roser, Medina, Luis Alberto, Mondragon-Fuentes, Laura, and Garcia-Lopez, Patricia
- Subjects
LIPOSOMES ,HELA cells ,CERVICAL cancer ,MIFEPRISTONE ,CISPLATIN ,DRUG side effects ,CELL cycle - Abstract
Cervical cancer is usually diagnosed in the later stages despite many campaigns for early detection and continues to be a major public health problem. The standard treatment is cisplatin-based chemotherapy plus radiotherapy, but patient response is far from ideal. In the research for new drugs that enhance the activity of cisplatin, different therapeutic agents have been tested, among them the antiprogestin mifepristone. Nevertheless, the efficacy of cisplatin is limited by its low specificity for tumor tissue, which causes severe side effects. Additionally, cervical tumors often become drug resistant. These problems could possibly be addressed by the use of liposome nanoparticles to encapsulate drugs and deliver them to the target. The aim of this study was to prepare liposome nanoparticles that co-encapsulate cisplatin and mifepristone, evaluate their cytotoxicity against HeLa cells and in vivo with subcutaneous inoculations of xenografts in nu/nu mice, and examine some plausible mechanisms of action. The liposomes were elaborated by the reverse-phase method and characterized by physicochemical tests. The nanoparticles had a mean particle size of 109 ± 5.4 nm and a Zeta potential of −38.7 ± 1.2 mV, the latter parameter indicating a stable formulation. These drug-loaded liposomes significantly decreased cell viability in vitro and tumor size in vivo, without generating systemic toxicity in the animals. There was evidence of cell cycle arrest and increased apoptosis. The promising results with the co-encapsulation of cisplatin/mifepristone warrant further research. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
10. Real-World Efficacy and Safety of Plasma-Derived Von Willebrand Factor-Containing Factor VIII Concentrates in Patients With Von Willebrand Disease in Italy.
- Author
-
Federici AB, Santoro RC, Santoro C, Pieri L, Santi RM, Barillari G, Borchiellini A, Tosetto A, Zanon E, De Cristofaro R, Mairal E, and Mir R
- Subjects
- Humans, Italy, Male, Female, Retrospective Studies, Adult, Middle Aged, Adolescent, Young Adult, Child, Aged, Child, Preschool, von Willebrand Diseases drug therapy, von Willebrand Factor therapeutic use, Factor VIII therapeutic use
- Abstract
Plasma-derived von Willebrand factor-containing factor VIII concentrates (pd-VWF/FVIII-C) are the mainstay of treatment in von Willebrand disease (VWD). Real-world data on efficacy and safety of these pd-VWF/FVIII-C are required. To retrospectively evaluate the efficacy and safety of pd-VWF/FVIII-C (Fanhdi® and Alphanate®, Grifols) in clinical practice in Italy. A multicentric, observational, retrospective study at 10 Italian centers was conducted. Eligible patients diagnosed with inherited VWD (ISTH criteria) were treated with either Fanhdi® or Alphanate® for bleeding episodes, prevention of surgical bleeding and secondary long-term prophylaxis (SLTP) according to clinical practice with medical records collected from January 2007 to December 2019. Efficacy/safety of pd-VWF/FVIII-C was assessed according to FDA-agreed objective criteria following regulatory procedures. Fifty-seven patients (M/F: 21/36) were enrolled in the study with the following VWD types: VWD1 (n = 29, 52%), VWD2A (n = 10, 18%), VWD2B (n = 7, 12%), VWD2M (n = 2, 4%), VWD2N (n = 1, 2%), VWD2 unclassified (n = 1, 2%), and VWD3 (n = 7, 12%). These pd-VWF/FVIII-C were used to manage 58 bleeding episodes (n = 24 patients), 100 surgeries (n = 47 patients), and 7 SLTP (n = 6 patients). Global clinical efficacy with these pd-VWF/FVIII-C was reported to be excellent/good in 85% of bleeding episodes, 98% of surgeries, and 100% of SLTP. As far as safety, no adverse-drug-related episodes, immunogenic or thrombotic events were reported. This study confirmed that Fanhdi® and Alphanate® were effective and safe in the management of bleeding episodes, the prevention of bleeding during surgeries and for SLTP in Italian patients with inherited VWD., Competing Interests: Declaration of Conflicting InterestsR. Mir is full-time employee of Grifols. E. Mairal is a former full-time employee of Grifols. A.B. Federici has been involved in advisory boards of Baxalta/Shire/Takeda, CSL Behring, Grifols, Kedrion, LFB and Octapharma with honoraria related to VWD. The remaining authors declare that there is no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.
- Published
- 2024
- Full Text
- View/download PDF
11. Clinical Efficacy and Safety of Fanhdi ® , a Plasma-Derived VWF/Factor VIII Concentrate, in von Willebrand Disease in Spain: A Retrospective Study.
- Author
-
Jiménez-Yuste V, Alvarez-Román MT, Palomo Bravo Á, Galmes BJ, Nieto Hernández MDM, Benítez Hidalgo O, Marzo Alonso C, Pérez González NF, Coll J, Núñez R, Carrasco M, García Candel F, Gonzalez-Porras JR, Hernández García C, Varó Castro MJ, and Mir R
- Subjects
- Adolescent, Adult, Aged, Blood Loss, Surgical prevention & control, Child, Drug Combinations, Factor VIII administration & dosage, Female, Hemostatics administration & dosage, Humans, Male, Middle Aged, Retrospective Studies, Spain, Young Adult, von Willebrand Factor administration & dosage, Factor VIII therapeutic use, Hemorrhage drug therapy, Hemorrhage etiology, Hemostatics therapeutic use, von Willebrand Diseases complications, von Willebrand Factor therapeutic use
- Abstract
Objective: To evaluate the efficacy and safety of a plasma-derived factor VIII concentrate containing von Willebrand Factor (pdVWF/FVIII) in standard clinical practice in von Willebrand Disease (VWD) patients., Methods: A retrospective, multicentric, observational study of VWD patients treated with Fanhdi
® , a pdVWF/FVIII concentrate, from January 2011 to December 2017 was conducted at 14 centers in Spain. Efficacy and safety were evaluated for acute bleeding episodes, for prevention of bleeding in surgeries, and for secondary long-term prophylaxis., Results: Seventy-two eligible patients, type 1, 2, 3 VWD (25%/38.9%/36.1%) were treated for spontaneous and traumatic bleeding (140 episodes, n = 41 patients), to prevent surgical bleeding (69 episodes, n = 43 patients); and for secondary long-term prophylaxis (18 programs, n = 13 patients). Replacement therapy with pdVWF/FVIII showed an excellent to good clinical efficacy in 96.7% of the bleeding episodes, 100% during surgical procedures and 100% during prophylaxis. No adverse events (AEs), nor serious AEs related to the product were observed., Conclusions: Fanhdi® was effective, safe and well tolerated in the management of bleeding episodes, the prevention of bleeding during surgeries, and for secondary long-term prophylaxis in VWD patients.- Published
- 2022
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.